Barrington Research Reaffirms Outperform Rating for Option Care Health (NASDAQ:OPCH)

Barrington Research restated their outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a report issued on Wednesday morning, Benzinga reports. They currently have a $38.00 price objective on the stock. Barrington Research also issued estimates for Option Care Health’s FY2024 earnings at $1.15 EPS, Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $1.35 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group boosted their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a buy rating in a report on Monday, March 4th.

Option Care Health Trading Up 1.1 %

Shares of Option Care Health stock opened at $29.61 on Wednesday. Option Care Health has a 52-week low of $24.23 and a 52-week high of $35.74. The company has a quick ratio of 1.33, a current ratio of 1.77 and a debt-to-equity ratio of 0.74. The company’s 50-day simple moving average is $31.96 and its 200-day simple moving average is $31.48. The firm has a market cap of $5.15 billion, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 1.45 and a beta of 1.22.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The firm’s revenue was up 12.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.21 earnings per share. As a group, equities research analysts anticipate that Option Care Health will post 1.18 earnings per share for the current year.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of Option Care Health stock in a transaction on Monday, February 26th. The shares were bought at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the completion of the acquisition, the director now directly owns 269,528 shares of the company’s stock, valued at $8,503,608.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Several institutional investors and hedge funds have recently modified their holdings of OPCH. Principal Securities Inc. purchased a new stake in shares of Option Care Health in the fourth quarter valued at about $27,000. Parallel Advisors LLC lifted its stake in shares of Option Care Health by 130.2% during the fourth quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock valued at $28,000 after buying an additional 478 shares during the period. TFO Wealth Partners LLC lifted its stake in shares of Option Care Health by 24,625.0% during the fourth quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock valued at $33,000 after buying an additional 985 shares during the period. First Horizon Advisors Inc. purchased a new position in shares of Option Care Health during the third quarter valued at approximately $37,000. Finally, Park Place Capital Corp lifted its stake in shares of Option Care Health by 48.4% during the first quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock valued at $38,000 after buying an additional 372 shares during the period. Hedge funds and other institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.